BioSpace News Archive

No longer on the periphery of the life sciences market, nonprofit groups are bridging the gaps in drug discovery and development.

Following the J.P. Morgan Healthcare Conference and other parallel meetings in San Francisco, it’s time to reflect on some of the significant deals secured last week.

Medivir AB announced that clinical pharmacokinetic data from the first study with fostroxacitabine bralpamide will be presented at the European Association for the Study of the Liver Liver Cancer Summit in February 22-24, 2024 in Rotterdam.

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of January 2024, which is payable on February 15, 2024 to shareholders of record at the close of business on January 31, 2024.

Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA, released findings of its comprehensive Veterinary Wellbeing Study conducted in collaboration with the American Veterinary Medical Association.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), (“Defence” or the “Company”), one of the leading Canadian biotechnology companies working in the field of immune-oncology is pleased to announce that it arranges a financing, and its common shares have been upgraded to OTCQB.

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that it received a transparency notification from the shareholders listed below, notifying the number of voting rights attached to shares mentioned next to their respective names in the table below.

AnX Robotica is thrilled to announce FDA clearance for expanded indications of its NaviCam Small Bowel Video Capsule Endoscopy in both adults and children aged 2 years and above.

A new international biotech group was born from the integration of Hyris Ltd, an innovative biotech company renowned worldwide for its disruptive genetic testing platform, and Ulisse Biomed S.p.A., also known as UBM Group or “UBM” only, an Italian-based publicly traded biotech company appreciated for its innovative testing platforms.

Arthrex, a global leader in minimally invasive surgical technology and surgical skills education, has launched a new patient-focused resource, TheNanoExperience.com, highlighting the science and benefits of Nano arthroscopy, a modern, least-invasive orthopedic procedure that may allow for a quick return to activity and less pain.